Takeda Pharmaceutical's Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options. Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company's top overall product faces patent expirations.
Takeda Pharmaceutical's Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options.
Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company's top overall product faces patent expirations.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
Takeda Pharmaceutical's Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options. Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company's top overall product faces patent expirations.
Open the app view to save this story, compare related coverage, and continue from the same source.